Once-daily antiretroviral therapy: Spanish Consensus Statement

• Published in: Journal of antimicrobial chemotherapy Vol. 56; no. 5; pp. 808 - 818
• Main Authors: Pulido, F., Ribera, E., Moreno, S., Muñoz, A., Podzamczer, D., del Pozo, M. A., Rivero, A., Rodríguez, F., Sanjoaquín, I., Teira, R., Viciana, P., Villalonga, C., Antela, A., Carmena, J., Ena, J., Gonzalez, E., Kindelán, J. M., Mallolas, J., Márquez, M., Martínez, E.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford Oxford University Press 01.11.2005; Oxford Publishing Limited (England)
• Subjects: Anti-HIV Agents - administration & dosage; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral Therapy, Highly Active; antiretrovirals; Biological and medical sciences; HAART; HIV Infections - drug therapy; HIV therapy; Human viral diseases; Humans; Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Infectious diseases; Medical sciences; Pharmacology. Drug treatments; Spain; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Europe; Spain; Immunopathology; Antiretroviral agent; Retroviridae; AIDS; HIV therapy; Immune deficiency; Lentivirus; Consensus; Infection; Virus; Chemotherapy; Treatment; antiretrovirals; Viral disease; Antiviral; Human immunodeficiency virus; HAART
• ISSN: 0305-7453; 1460-2091
• DOI: 10.1093/jac/dki320

Background: Administration of antiretroviral therapy (ART) once daily is creating extraordinary interest among the members of the scientific community and also among those who receive the therapy. However, in clinical practice, some doubts remains about its use. Objectives: This document examines the characteristics and possibilities of treatment administered once daily. Methods: Consensus of 248 Spanish experts in the field. Results: Once-daily dosing is considered an added value which could favour adherence and, therefore, efficacy, as well as the quality of life of certain patients, however, the objective of adequate adherence in the long term is often difficult to achieve regardless of the treatment used. In theory, any patient can receive once-daily therapy, although some patients could particularly benefit from it, e.g. those with unfavourable social or personal circumstances, including drug users, patients whose treatment must be supervised, patients receiving multiple medications, or those who need rescue therapy after multiple treatment failures. At present, it is possible to design once-daily ART using some of the combinations of drugs considered as first-choice in national and international recommendations for antiretroviral therapy, but the options are still limited. The marketing of new drugs with this characteristic could allow us to increase the number and types of patient who can benefit from once-daily regimens, including those patients who need rescue therapy. Conclusions: Once-daily ART is a good alternative to regimens administered several times each day when a potent combination of active drugs is available.